The Status of the Standard of Care for Cancer Patients

Alex A. Adjei, MD, PhD, FACP

Video Categories: Personalized Medicine

Dr. Alex Adjei discusses how the standard of care for cancer patients has improved overt he last few years, but there is still a great need for new treatments designed to help a broader range of cancer patients.

March 31, 2015

Ibrutinib and ABT199 for CLL

Jennifer R. Brown, MD, PhD, at Dana-Farber Cancer Institute in Boston, discusses what she believes are the most important items coming out of ASH for CLL this year. She mentions excellent study results being presented about the drugs ibrutinib and ABT199.

January 30, 2014

Communicating Value of Personalized Medicine to All Stakeholders in Healthcare

Listen as Dr Argawala articulates the value proposition of personalized medicine for all stakeholders in healthcare.